Fundraising FoxCommodore Capital — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsAccess BiotechnologyAndreessen HorowitzBAM ElevateBay City CapitalEIR VenturesForbion+7 more
A biotechnology company developing new therapies for patients with high unmet medical needs.
Biotech
Co-investorsDolby Family VenturesLifeSci Venture PartnersSofinnova VenturesThe W FundFranklin TempletonLigand Pharmaceuticals+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.